Patrick Lavery

In the first part of an extended video interview, Petra Dieterich and Jeffrey Mocny of Abzena emphasize that every part of the process of developing novel biologics is designed to bring them to humans not just quickly, but also safely.

In an expansion of his written three-part series for PharmTech, Jason Bryant of ArisGlobal explains the interplay between autonomy and accountability that is essential for AI agents assisting the pharmaceutical industry.

The complications of conjugate molecules, such as oligonucleotides, are explored in this second portion of an interview with Abzena experts.

ArisGlobal’s Jason Bryant continues a video supplement to his series of articles on the adoption and implementation of AI agents.

In the concluding segment of a multi-part interview, Jason Bryant of ArisGlobal explains how human-in-the-loop and human-on-the-loop are both still relevant in AI implementation in pharma.

In the final part of an interview with Petra Dieterich and Jeffrey Mocny of Abzena, the current tariff situation in the United States and beyond is considered.

The Federal Circuit recently confirmed the importance of properly identifying the trade secrets underlying a claim under the Ohio Uniform Trade Secrets Act (“OUTSA”) [ Ohio Rev. Code §§ 1333.61 et seq. ], finding that the plaintiffs' failure to properly identify the trade secrets entitled the defendant to judgment as a matter of law notwithstanding a jury verdict in the plaintiffs' favor.

The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to another.

Secondary packaging is increasingly becoming a darling of companies’ smart technologies and sustainability goals.